Background
The incidence of inflammatory bowel disease (IBD) is increasing worldwide including Denmark. [1] [2] [3] [4] During the last decades, introduction of biological therapy has changed the management of ulcerative colitis (UC) and Crohn's disease (CD). 5 As a consequence, the medication-related expenses of IBD therapy have increased substantially. 6 International and national treatment guidelines support clinicians in treatment decisions and rational clinical use of biological therapy and are used by health care providers to prioritize and regulate the costs of therapy.
Aim of The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease
To ensure a rational use of biological drugs and adherence to national guidelines, The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease 
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Larsen et al (BIO-IBD) has been established in 2015. First, the aim of the database is to ensure that the choice of biological therapy and the clinical management of patients with IBD receiving biological treatment are in accordance with the national clinical guidelines 7 and second, the database can be used for register-based clinical epidemiological research.
The database is planned to start in March 2016, and patients will be enrolled consecutively when biological treatment is initiated. Based on recent data from The Danish National Patient Registry (NPR), we estimate that 1,200-1,300 new biological therapies are initiated each year and at a given point in time 2,700-2,800 patients are treated with biological agents.
Study population
In Denmark (population of ∼5.5 million people), all citizens have free access to a tax-supported health care system, and biological therapy is only administered in public hospitals without cost to the patient. 8 For all Danish hospitals, both public and private, it is mandatory by Danish law to report diagnosis and clinical procedures to NPR. The completeness of coding in NPR is very high as 99% of all hospital discharges and out-patient clinics from somatic hospitals are recorded. 9 Likewise the completeness of diagnoses of IBD in NPR is very good. In one study, the validity of the IBD diagnoses in NPR was examined using the pathology system as a reference standard, confirming that 94% of the UC and CD diagnoses were included in the NPR. The overall validity of diagnoses of CD in the NPR was 97%, and for UC 90%. 10 Identification of patients is based on the Danish Civil Registration System (CRS). The CRS has registered all persons alive and living in Denmark since 1968, and has a very high accuracy of Danish citizens and migrations. 11, 12 The availability of these nationwide Danish registries makes it possible to retrieve data on almost all patients with IBD and treatment with biological agents. Hence, the study population comprises all Danish patients with IBD (both children and adults) with UC, CD, and IBD-unclassified (IBD-U) who receive biological therapy. Patients will be enrolled consecutively when biological treatment is initiated. Eligible patients with IBD are bio-naive patients (patients never treated with biological therapy); patients previously treated with biological therapy and stopped for .3 months, and patients already on biological therapy who, due to side effects or lack of effect, switch to another biological drug.
It is mandatory for the departments prescribing biological therapy to report these data to the BIO-IBD registry.
Quality indicators
Eleven quality indicators have been defined (Table 1) . Choice, background, and level of evidence for the indicators 
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The Danish National Registry: BiO-iBD are described in The BIO-IBD Documentarist Report. 13 Indicators related to outcome represent clinically relevant measures, with indicator standards determined from existing literature. Indicators related to process are addressing guideline adherence and administrative issues, with indicator standards determined from consensus in the working group. In the future, new quality indicators are to be defined and added to the registry.
Main variables
The variables in the database are obtained by two methods: Data from NPR are used for registration of the IBD patient and basic information on diagnosis, use of biologic agent, and IBD-related procedures. This is supplemented with clinical information reported by the clinician using a national webbased input module (Supplementary materials 1, 2, and 3 ). This is believed to ensure the best possible data quality. 1. Data harvested from NPR: diagnosis, previous biological therapy, surgery, endoscopic procedures, radiology, treatment dates regarding current biological therapy, and current biological agent ( 
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Larsen et al
• Pediatric Ulcerative Colitis Activity Index for children with UC and IBD-U
17
• Short Health Scale. 18, 19 A complete list of the variables can be found in Supplementary material 2.
Data recording
The clinician is required to ensure that every eligible patient is entered into the database upon start of biological therapy. It is recommended that data are entered in the database every time biological treatment is administered, but as a minimum twice yearly and every time changes in therapy, or side-effects occur or if therapy is stopped. In addition to this, there is a continuous data collection from the NPR, which will ensure that all eligible patients are registered, should the clinician fail to include the patient at the first visit. To ensure the completeness of the database, the departments involved in administering biological treatment will receive lists of patients with records of biological treatment codes from the NPR.
The quality of data in the database relies entirely on the clinician/IBD nurse and is the responsibility of the department giving biological treatment. It will only be possible to calculate the quality indicators if sufficient data is reported in the database. If it is not possible to calculate the indicators, the departments with incomplete data will be mentioned in the annual report. There is no official quality control but as the results are a public document and reported on a quarterly basis to the departments to regularly review their clinical performance, it is believed to motivate the clinicians to high quality in both treatment and reporting.
Examples of research
The database will be available for research during 2016. Data will be made available by The Danish Clinical Registries (RKKP; www.rkkp.dk).
Administrative issues and funding
The database is administered by a steering committee, which comprises:
• Five members of the Danish Society of Gastroenterology and Hepatology (one member from each of the five regions in Denmark) • A pediatric gastroenterologist, member of the Danish Pediatric Society • A documentarist (clinician to compose a report on the background and evidence for the indicators) 
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The Danish National Registry: BiO-iBD approval is not required according to Danish law when data are used to monitor, secure, and improve clinical quality.
Conclusion
Based on the indicators defined, an annual report will state the quality of biological therapy in patients with IBD treated in Denmark, both at a national and department level together with a complete overview of the data available. In addition, results are reported on a quarterly basis to the departments to regularly review their clinical performance. The indicators will be reported as department-specific proportions with 95% confidence intervals, and the national average will be provided for comparison. For each indicator, a standard has been developed based on the available evidence. • A RKKP-team (Danish Clinical Quality Databases represented by the Centre of Competence for Nationwide Clinical Registries) assigning a contact person, a data manager, an epidemiologist, and a statistician. The members are appointed for a period of 4 years by the board of the respective societies. There is an option for one re-election.
The steering committee has no financial means of its own, but the Danish Regions' funding for clinical quality registries has secured a grant for the establishment of the database. 
